Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized adjuvant chemotherapy individualized by BRCA1 mRNA levels in resected stage II–IIIA non-small cell lung cancer
2007-000067-15Phase 3Completed
- Sponsor
- Fundación GECP
- Start
- Mar 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of docetaxel, gemcitabine and cisplatin in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Fundación GECP. Primary endpoints: Overall survival and Disease progression. Started Mar 2007; status: completed.
02
Drugs
docetaxelgemcitabinecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-000067-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000067-15.